Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen At A Crossroads: Analysts Question Capital Allocation, M&A,D-mab

Executive Summary

Amgen Inc. is going through a transformational time as many of its top-selling drugs are maturing and its latest potential blockbuster franchise tries to find a foothold in the market. While Prolia/Xgeva (denosumab) offers a lucrative lifeline for the big biotech, investors are getting anxious about the company’s future; pushing for a dividend and for clarity about its strategy.

You may also be interested in...



A Maturing Amgen Focuses On Capital Allocation, Late-Stage Pipeline

Even as it reaffirms its big long-term bet on R&D, Amgen appeases investors with tweaks to its R&D organization and expansion of its share buyback program.

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2011

Biopharma companies raised $3.6 billion in Q1, with almost two-thirds coming from debt sales or follow-on public offerings. Seven of the 19 finalized mergers topped $500 million, but the biggest news was Valeant's attempt to takeover Cephalon. Lilly and BI signed the biggest deal of the quarter when they pooled their diabetes assets in an alliance worth $2.4 billion.

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2011

Biopharma companies raised $3.6 billion in Q1, with almost two-thirds coming from debt sales or follow-on public offerings. Seven of the 19 finalized mergers topped $500 million, but the biggest news was Valeant's attempt to takeover Cephalon. Lilly and BI signed the biggest deal of the quarter when they pooled their diabetes assets in an alliance worth $2.4 billion.

Related Content

Topics

UsernamePublicRestriction

Register

PS053299

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel